Literature DB >> 23975359

Assessment of the dimensions, construct validity, and utility for rheumatoid arthritis screening of the COPCORD instrument.

José Moreno-Montoya1, José Alvarez-Nemegyei, Belem Trejo-Valdivia, Ingris Peláez-Ballestas.   

Abstract

This study aims to evaluate the structural validity of the Community-Oriented Program for the Control of Rheumatic Diseases (COPCORD) core instrument as a screening tool for rheumatoid arthritis (RA) by means of assessing the existence of domains in the questionnaire. The Mexican version of the COPCORD instrument was applied to individuals over18 years of age in five regions of the country through a probabilistic/convenience household survey. Clinical confirmation of RA diagnosis was used. The variables analyzed included self-reported comorbidities and manifestations of the disease, as well as sociodemographic characteristics. The statistical approach was based on polychoric exploratory factor analysis and confirmatory factor analysis by means of probit structural equation models. A total of 19,213 subjects were included in the analysis. The average age for the total sample was 42.89 years old; 40.64 % of the subjects were older than 45 years of age and 20.42 % older than 55. More than 80 % of the variation was related to three underlying factors: recent pain, historical pain, and disability. The findings verified the usefulness of the COPCORD instrument as a screening tool for RA. The results also allowed to characterize how the variation in terms of manifestations of the disease could be accounted for diagnosing the disease in the Mexican context and examined the capabilities of the instrument to measure correctly the main characteristics of patients suffering from RA.

Entities:  

Mesh:

Year:  2013        PMID: 23975359     DOI: 10.1007/s10067-013-2367-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

1.  Development of a questionnaire for identification of the risk factors for osteoarthritis of the knees in developing countries. A pilot study in Iran and Bangladesh. An ILAR-COPCORD phase III study.

Authors:  Syed Atiqul Haq; Fereydoun Davatchi; Saeideh Dahaghin; Nazrul Islam; Aniruddha Ghose; John Darmawan; Arvind Chopra; Zeng Quing Yu; Leonila F Dans; Johannes J Rasker
Journal:  Int J Rheum Dis       Date:  2010-08       Impact factor: 2.454

2.  An empirical evaluation of alternative methods of estimation for confirmatory factor analysis with ordinal data.

Authors:  David B Flora; Patrick J Curran
Journal:  Psychol Methods       Date:  2004-12

Review 3.  Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review.

Authors:  Yannis Alamanos; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Semin Arthritis Rheum       Date:  2006-10-11       Impact factor: 5.532

4.  Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology.

Authors:  Ingris Peláez-Ballestas; Luz Helena Sanin; José Moreno-Montoya; José Alvarez-Nemegyei; Rubén Burgos-Vargas; Mario Garza-Elizondo; Jacqueline Rodríguez-Amado; Maria-Victoria Goycochea-Robles; Marco Madariaga; Jorge Zamudio; Natalia Santana; Mario H Cardiel
Journal:  J Rheumatol Suppl       Date:  2011-01

5.  Community screening for rheumatic disorder: cross cultural adaptation and screening characteristics of the COPCORD Core Questionnaire in Brazil, Chile, and Mexico. The PANLAR-COPCORD Working Group. Pan American League of Associations for Rheumatology. Community Oriented Programme for the Control of Rheumatic Disease.

Authors:  K Bennett; M H Cardiel; M B Ferraz; P Riedemann; C H Goldsmith; P Tugwell
Journal:  J Rheumatol       Date:  1997-01       Impact factor: 4.666

Review 6.  A meta-analysis of mortality in rheumatic diseases.

Authors:  Esther Toledano; Gloria Candelas; Zulema Rosales; Cristina Martínez Prada; Leticia León; Lydia Abásolo; Estíbaliz Loza; Loreto Carmona; Aurelio Tobías; Juan Ángel Jover
Journal:  Reumatol Clin       Date:  2012-07-11

7.  Validation of the Health Assessment Questionnaire disability index in patients with gout.

Authors:  Everardo Alvarez-Hernández; Ingris Peláez-Ballestas; Janitzia Vázquez-Mellado; Leobardo Terán-Estrada; Ana Guishlaine Bernard-Medina; Jesús Espinoza; Francisco J Aceves-Avila; María V Goycochea-Robles; Mario Garza; Lucio Ventura; Rubén Burgos-Vargas
Journal:  Arthritis Rheum       Date:  2008-05-15

8.  [Health-related quality of life in Korean patients with rheumatoid arthritis: association with pain, disease activity, disability in activities of daily living and depression].

Authors:  Dong Choon Uhm; Eun Sook Nam; Ho Yeon Lee; Eun Bong Lee; Young Im Yoon; Gong Ju Chai
Journal:  J Korean Acad Nurs       Date:  2012-06       Impact factor: 0.984

9.  Old and new ideas for data screening and assumption testing for exploratory and confirmatory factor analysis.

Authors:  David B Flora; Cathy Labrish; R Philip Chalmers
Journal:  Front Psychol       Date:  2012-03-01

10.  The use of mixed models for the analysis of mediated data with time-dependent predictors.

Authors:  Emily A Blood; Debbie M Cheng
Journal:  J Environ Public Health       Date:  2011-05-14
View more
  3 in total

1.  Severe tophaceous gout and disability: changes in the past 15 years.

Authors:  Carlos Omar López López; Everardo Fuentes Lugo; Everardo Alvarez-Hernández; Ingris Peláez-Ballestas; Rubén Burgos-Vargas; Janitzia Vázquez-Mellado
Journal:  Clin Rheumatol       Date:  2016-09-08       Impact factor: 2.980

2.  Mexican rheumatology: where do we stand?

Authors:  Carlos Pineda; Hugo Sandoval; Antonio Fraga-Mouret
Journal:  Rheumatol Int       Date:  2018-11-12       Impact factor: 2.631

3.  Prevalence of rheumatic diseases in Raramuri people in Chihuahua, Mexico: a community-based study.

Authors:  Danyella Del Río Nájera; Natalia Santana; Ingris Peláez-Ballestas; Susana A González-Chávez; Celia M Quiñonez-Flores; César Pacheco-Tena
Journal:  Clin Rheumatol       Date:  2016-03-08       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.